Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder

NCT00343356 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

138

Enrollment

OTHER

Sponsor class

Conditions

Bladder Neoplasms

Interventions

DRUG: Trement

Sponsor

LanZhou University